Emily Bristow Archives

Bringing home the bacon – or are you?

by Naomi Pearce, Emily Dwyer | Aug 2, 2022 | Blog, Emily Bristow, Naomi Pearce

Introduction Plant based protein products are already a well established destination in the supermarket aisle. Australia is reportedly the third fastest growing market for such products. As technology finds ways to replicate more and more closely traditional meat...

Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways

by Kate Legge, Emily Dwyer, Naomi Pearce | May 10, 2022 | Blog, Emily Bristow, Kate Legge, Naomi Pearce

Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG). Rather, they are unapproved therapeutic goods, i.e., products that have not been assessed...

Psychedelic Medicines Part 1

by Naomi Pearce, Emily Dwyer | May 4, 2022 | Blog, Emily Bristow, Naomi Pearce

Depression, anxiety and related disorders are serious conditions whose treatment is – in many cases – not adequately addressed by existing psychiatric or psychological therapies. Despite the efforts of those seeking to develop novel treatments for these...

Medicinal Cannabis in Australia | Part 1: Available Products

by Emily Dwyer, Naomi Pearce | May 4, 2022 | Blog, Emily Bristow, Naomi Pearce

Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG). Rather, they are unapproved therapeutic goods, i.e., products...

Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap

by Naomi Pearce, Emily Dwyer | Apr 14, 2022 | Blog, Emily Bristow, Naomi Pearce

In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA from threatening patent infringement proceedings against UbiPark’s customers pending judgment on the merits in the litigation. This case, UbiPark Pty...

Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed

by Naomi Pearce, Emily Dwyer | Apr 5, 2022 | Blog, Emily Bristow, Naomi Pearce

In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator pharmaceutical companies that prevent generic versions of their drugs from listing on the PBS through unwarranted injunctions. In patent litigation...